Last CNY15.09 CNY
Change Today 0.00 / 0.00%
Volume 0.0
As of 3:00 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

hainan shuangcheng pharmac-a (002693) Snapshot

Open
CNY15.19
Previous Close
CNY15.09
Day High
CNY15.27
Day Low
CNY14.96
52 Week High
02/17/14 - CNY17.90
52 Week Low
06/25/13 - CNY9.78
Market Cap
2.7B
Average Volume 10 Days
1.4M
EPS TTM
CNY0.37
Shares Outstanding
180.0M
EX-Date
--
P/E TM
40.8x
Dividend
CNY0.20
Dividend Yield
1.55%
Current Stock Chart for HAINAN SHUANGCHENG PHARMAC-A (002693)

Related News

No related news articles were found.

hainan shuangcheng pharmac-a (002693) Related Businessweek News

No Related Businessweek News Found

hainan shuangcheng pharmac-a (002693) Details

Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and marketing of chemically synthesized peptide drugs. Its products include APIs and formulations. The company provides Thymalfasin for injection, which is used for the treatment of chronic hepatitis B, as well as used as a vaccine for patients with immune system functions suppressed; Levocarnitine for injection; and . It also offers Thymopentin for injection for treating chronic hepatitis B; various primary or secondary T cell immunodeficiency diseases, such as children innate immunodeficiency disease; autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, etc.; various diseases with impaired cell immunity functions; and supplementary treatment of rumor diseases. In addition, the company provides Clindamycin Hydrochloride for injection for amygdalitis, suppurative otitis media, and nasosinusitis; acute bronchitis, acute episode of chronic bronchitis, pneumonia, lung abscess, and bronchiectasia concurrent infection; skin and soft tissue infections; urinary system infection, acute urethritis, acute pyelonephritis, and prostatitis; and osteomyelitis, septicemia, peritonitis, and oral infection. Further, it offers Famotidine for injection for patients with peptic ulcer hemorrhage; and intercurrent acute gastric mucosal lesion under stress condition, and gastrointestinal bleeding that is caused by nonsteroidal anti-inflammatory drugs. Additionally, the company provides Somatostatin for injection for treating acute haemorrhage from oesophageal varices; acute haemorrhage from gastric or duodenal ulcers, or accompanying acute erosive or haemorrhagic gastritis; pancreas, gallbladder, and intestinal fistula; prophylaxis; and diabetic ketoacidosis, as well as for treating postoperative complications following pancreatic surgery. Hainan Shuangcheng Pharmaceuticals Co., Ltd. is based in Haikou, the People’s Republic of China.

Founded in 2010

hainan shuangcheng pharmac-a (002693) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hainan shuangcheng pharmac-a (002693) Key Developments

Hainan Shuangcheng Pharmaceutical Co., Ltd. Proposes Amendments to the Articles of Association

Hainan Shuangcheng Pharmaceutical Co., Ltd. proposed amendments to the articles of association of the company.

Hainan Shuangcheng Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Apr 15, 2014

Hainan Shuangcheng Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Apr 15, 2014., at 14:50 China Standard Time. Agenda: To consider amendments to the articles of association of the Company; and to consider use of idle raised and over raised funds to purchase bank wealth management products.

Hainan Shuangcheng Pharmaceutical Co., Ltd. to Report Fiscal Year 2013 Results on Apr 10, 2014

Hainan Shuangcheng Pharmaceutical Co., Ltd. announced that they will report fiscal year 2013 results on Apr 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002693:CH CNY15.09 CNY 0.00

002693 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002693.
View Industry Companies
 

Industry Analysis

002693

Industry Average

Valuation 002693 Industry Range
Price/Earnings 37.6x
Price/Sales 16.4x
Price/Book 3.3x
Price/Cash Flow 37.9x
TEV/Sales 13.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAINAN SHUANGCHENG PHARMAC-A, please visit www.shuangchengmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.